Physicians' Academy for Cardiovascular Education

SGLT2 inhibitor reduces CV death and hospitalization for HF, especially in those with HF at baseline

Canagliflozin For Prevention Of Heart Failure In Type 2 Diabetes: Results From The CANVAS Program

Presented at ACC.18 by Gemma Figtree (Royal North Shore Hospital, University of Sydney, Australia)

News - Mar. 12, 2018

Introduction and methods

The randomized CANVAS study evaluated the SGLT2 inhibitor canagliflozin 300 mg and 100 mg in comparison with placebo, in patients with type 2 diabetes (T2DM, HbA1c between 7.0% and 10.5%, eGFR≥30 mL/min/1.73m² and at least 30 years old, with a history of CV event, or at least 50 years old with at least 2 CV risk factors). Of 10142 patients enrolled, 1461 (14.4%) had a prior diagnosis of heart failure (HF) and 85.6% did not.

Effects of canagliflozin on CV and renal outcomes have previously been published, including a 14% reduction in the composite endpoint of CV death, nonfatal MI and nonfatal stroke, lower progression of albuminuria (-27%) and a 40% lower risk of a renal composite endpoint. The objectives of this analysis were to explore in further detail the effects of canagliflozin on HF, and to determine efficacy and safety in patients with and without a history of HF at baseline.

Main results

Conclusion

This analysis of the CANVAS study shows that among patients with T2DM and an elevated risk of CVD, canagliflozin lowered the risk of CV death or HHF across a broad range of patient groups. This analysis showed that patients with a history of HF at baseline benefit more from treatment with canagliflozin. There was no evidence for a difference in the safety profile based on the diagnosis of heart failure at baseline.

Disclosures

Our coverage of ACC.18 is based on the information provided during the congress.

This study was published simultaneously in Circulation